ConductScience.org, home

Paper350387

A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate.

Pannuti F and 4 others. Cancer Treat Rep, 1978. Cited by 101 papers, by iCite.

Cite this record

ConductScience Library. A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate. Papers, record 350387. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/350387

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate.
PubMed
Journal
Cancer Treat Rep
PubMed
Year
1978
PubMed
Publication types
Clinical Trial, Journal Article
PubMed
Citations, by iCite
101
iCite
Relative citation ratio, by iCite
4.11
iCite
Revised in PubMed
2013-11-21
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pannuti FF
2Martoni AA
3Lenaz GRG R
4Piana EE
5Nanni PP

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
MedroxyprogesteroneMajor topic
Adult
Aged
Clinical Trials as Topic
Female
Humans
Male
Middle Aged
Neoplasm Metastasis
Time Factors

Source PubMed

Download CSV of topics

Cited by22

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 101 citations.

PMIDTitleJournalYearIn PapersSource
12172571The role of aromasin in the hormonal therapy of breast cancer.Pathol Oncol Res2002https://conductscience.org/library/papers/12172571PubMed
11091543Benefits of Medroxyprogesterone Acetate (MPA) in Advanced or Recurrent Breast Cancer with Higher Serum Concertration.Breast Cancer1995https://conductscience.org/library/papers/11091543PubMed
9443650Correlation of expression levels of P-glycoprotein with resistance to adriamycin in a renal adenocarcinoma cell line.Urol Res1997https://conductscience.org/library/papers/9443650PubMed
7438329Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes.Cancer Chemother Pharmacol1980https://conductscience.org/library/papers/7438329PubMed
6400037Chemotherapy of breast cancer.Med Oncol Tumor Pharmacother1984https://conductscience.org/library/papers/6400037PubMed
6225476Current status of high dose progestin treatment in advanced breast cancer.Breast Cancer Res Treat1983https://conductscience.org/library/papers/6225476PubMed
6224604Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients.Cancer Chemother Pharmacol1983https://conductscience.org/library/papers/6224604PubMed
6224603A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer.Cancer Chemother Pharmacol1983https://conductscience.org/library/papers/6224603PubMed
6216931Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer. A preliminary report of clinical and experimental studies.Breast Cancer Res Treat1981https://conductscience.org/library/papers/6216931PubMed
6213319Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/6213319PubMed
3427228Alternating tamoxifen and medroxyprogesterone acetate in postmenopausal advanced breast cancer patients--short and long term endocrine effects.Breast Cancer Res Treat1987https://conductscience.org/library/papers/3427228PubMed
3156002Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancer.Cancer Chemother Pharmacol1985https://conductscience.org/library/papers/3156002PubMed
2986666Prostacyclin and thromboxane in breast cancer: relationship between steroid receptor status and medroxyprogesterone acetate.Br J Cancer1985https://conductscience.org/library/papers/2986666PubMed
2971386The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.Br J Cancer1988https://conductscience.org/library/papers/2971386PubMed
2963170On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer.Klin Wochenschr1987https://conductscience.org/library/papers/2963170PubMed
2952154The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients.Br J Cancer1987https://conductscience.org/library/papers/2952154PubMed
2939693Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA). A pilot study of five cases.Acta Neurochir (Wien)1986https://conductscience.org/library/papers/2939693PubMed
2570093Endocrine therapy of metastatic breast cancer.J Endocrinol Invest1989https://conductscience.org/library/papers/2570093PubMed
2524303Clinical significance of differences in bioavailability of medroxyprogesterone acetate preparations.Clin Pharmacokinet1989https://conductscience.org/library/papers/2524303PubMed
1828463Changes in hematologic parameters during treatment with medroxyprogesterone acetate for breast cancer.Jpn J Cancer Res1991https://conductscience.org/library/papers/1828463PubMed

See all 22 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/350387

GET https://conductscience.org/api/papers/v1/350387/cited_by?page=2